Eli Lilly and Company
LLYHealthcareNASDAQDrug Manufacturers - General · Last scanned May 29, 2026
Scan Results
Daily timeframePart of the healthcare sector, Eli Lilly and Company (LLY) is listed under Drug Manufacturers - General. The company carries a $985.37B market cap, placing it firmly in the mega-cap category. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Market Cap
$985.37B
Beta
0.48
P/E (TTM)
39.21
P/E (Fwd)
24.85
EPS (TTM)
$28.18
EPS (Fwd)
$44.47
ROE
107.5%
ROA
20.7%
Cash
$5.28B
Total Debt
$43.37B
Free CF
$9.16B
52W Change
47.9%
Annual Financials
Cash vs Debt
Eli Lilly and Company carries $43.37B in total debt against $5.28B in cash reserves — debt is roughly 8.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $9.16B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 107.5% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 20.7% further supports the picture of efficient asset utilization. Revenue has grown from $28.54B (2022) to $65.18B (2025), reflecting a 128% increase over the period.
With a beta below 0.7, Eli Lilly and Company typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LLY.